Alkermes Launches Competitive Grants Program to Support People Affected by Mental Health and Substance Use Disorders
September 12 2016 - 7:00AM
Business Wire
–– ALKERMESTM Inspiration Grants Will Award Up
to $1 Million for the Development or Expansion of Innovative
Community Programs ––
Alkermes plc (NASDAQ: ALKS), a global biopharmaceutical company
developing medicines for the treatment of central nervous system
(CNS) diseases, such as schizophrenia, major depressive disorder
and multiple sclerosis, today announced a new competitive grant
program. ALKERMESTM Inspiration Grants are designed to fund
high-impact programs that can be replicable through the ecosystem
for people affected by mental health and substance use disorders.
The application period is now open and will run until Oct. 7,
2016.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20160912005194/en/
“Medications are only one component of comprehensive care for
the millions of people affected by mental health and substance use
disorders,” said Richard Pops, Chief Executive Officer of Alkermes.
“With our patient-centric approach at the core of everything we do,
we created ALKERMES Inspiration Grants to fund innovative programs
that provide critical wraparound support services and have a
meaningful and substantive impact on individuals, families and
communities.”
Alkermes will award up to $1 million in grants for the
development or expansion of programs to support mental health and
addiction communities in two key areas: improving or enhancing
systems of care and/or ensuring the perspective of people affected
by mental illness or addiction is considered and reflected in the
development of medicines and delivery of care programs. Eligible
non-profit organizations may submit applications for grants of up
to $25,000 (Emergence Grant) or up to $100,000 (Innovation Grant).
Multiple submissions are permitted.
Submissions will be evaluated based on a set of standard
criteria and selected by Alkermes in partnership with an external
panel from the community, including a patient advocate, a
representative from the criminal justice system, a person in
addiction recovery and a caregiver for someone living with mental
illness.
“There is a palpable, sometimes debilitating, prejudice
associated with addiction and mental health issues, even for those
in recovery,” said Michael Miller, National Chapter Coordinator for
Young People in Recovery and member of the review committee for
ALKERMES Inspiration Grants. “Organizations that truly listen to
and learn from those affected by the diseases they support are
critical to the development of better, more effective medicines and
care programs. I am eager to see what innovative ideas the
community brings to the table. It’s truly inspiring.”
Only eligible U.S. 501(c)(3) non-profit organizations may apply.
These include, but are not limited to, patient organizations and
professional societies. The application process opened today and
closes on Oct. 7, 2016. Grants will be awarded to the chosen
organizations in November 2016, and funding will be distributed at
the end of the calendar year.
For more information on ALKERMES Inspiration Grants, including
the application, submission instructions and evaluation criteria,
visit www.alkermes.com/inspirationgrants.
About Alkermes
Alkermes plc is a fully integrated, global
biopharmaceutical company developing innovative medicines for the
treatment of central nervous system (CNS) diseases. The company has
a diversified commercial product portfolio and a substantial
clinical pipeline of product candidates for chronic diseases that
include schizophrenia, depression, addiction and multiple
sclerosis. Headquartered in Dublin, Ireland, Alkermes plc has an
R&D center in Waltham, Massachusetts; a research and
manufacturing facility in Athlone, Ireland; and a manufacturing
facility in Wilmington, Ohio. For more information, please visit
Alkermes’ website at www.alkermes.com.
Note Regarding Forward-Looking
Statements
Certain statements set forth in this press release constitute
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995, as amended. The company
cautions that forward-looking statements are inherently uncertain.
Although the company believes that such statements are based on
reasonable assumptions within the bounds of its knowledge of its
business and operations, the forward-looking statements are neither
promises nor guarantees and they are necessarily subject to a high
degree of uncertainty and risk. Actual performance and results may
differ materially from those expressed or implied in the
forward-looking statements due to various risks and uncertainties.
These risks and uncertainties include, among others, those risks
described in the Alkermes plc Annual Report on Form 10-K for the
fiscal year ended Dec. 31, 2015 and in other subsequent filings
made by the company with the U.S. Securities and Exchange
Commission (SEC), which are available on the SEC's website at
www.sec.gov. The information contained in this press release is
provided by the company as of the date hereof, and, except as
required by law, the company disclaims any intention or
responsibility for updating or revising any forward-looking
information contained in this press release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160912005194/en/
Alkermes plcFor Investors:Sandy Coombs, +1 781-609-6377orEva
Stroynowski, +1 781-609-6823orFor Media:Jennifer Snyder, +1
781-609-6166
Alkermes (NASDAQ:ALKS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alkermes (NASDAQ:ALKS)
Historical Stock Chart
From Apr 2023 to Apr 2024